The results of the tucatinib plus trastuzumab plus capecitabine regimen and the pyrotinib plus capecitabine regimen showed an improvement in overall response rate (ORR) in patients with HER2-positive breast cancer brain metastases (9, 10). Here, ERBB2 is linked to breast cancer.